Press Release
Breast Cancer Therapeutics Market Growth, Development by Top Players as Pfizer Inc., Sanofi and more till 2025
Breast Cancer Therapeutics Market Global Analysis, Industry Trend, Insights, Projection by 2025
The Global Breast Cancer Therapeutics Market, which stood at US$ 17,868.8 Mn in 2018, will reach [US$ 38,573.5 Mn] by the end of 2026. If these figures prove true, the global breast cancer therapeutics market will rise at a CAGR of 10.2% between 2018 and 2026.
Sample PDF [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/breast-cancer-therapeutics-market-100163
Some of the Main Key Players Covered in the Report
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- AstraZeneca
- Pfizer Inc.
- Sanofi
- Eisai Co. Ltd.
- Kyowa Kirin
- Bristol Myers Squibb
- Mayne Pharma Group Limited
- Valeant Pharmaceuticals
North America to Remain Dominant on Account of Presence of Skilled Professionals
The increasing number of breast cancer cases all over the world is anticipated to boost the global breast cancer therapeutics market at promising rates, finds Fortune Business Insights in a new study. The study is titled, “Breast Cancer Therapeutics Market: Global Market Analysis, Insights, and Forecasts”.
Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
The breast cancer treatment market in North America is currently leading the global landscape, supported by the presence of well-established healthcare infrastructure and rising uptake of advanced facilities in the region. In 2018, North America generated a revenue of US$ 8,033.8 Mn because of the increasing prevalence of breast cancer in the region.
In addition to this, the region boasts the presence of several leading market players and skilled professionals. Besides this, governments of developed nations such as Canada and the U.S. are providing health insurance for cancer diagnostics. Spurred by these factors the breast cancer therapeutics market is likely to flourish in North America to emerge dominant.
Key Segmentation:
By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
- Chemotherapy
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Cancer Type
- Hormone Receptor
- HER2+
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
High Intake of Oral Contraceptives Among Women, Boosting Market
Breast cancer can develop due to reasons such as reduced breastfeeding, rise in the age of childbearing, undergoing estrogen modifying drug treatments and high intake of oral contraceptive pills. The increase in the number of women complaining of such problems and the successive rise in the number of breast cancer cases are factors boosting the global market for breast cancer therapeutics during the forecast period.
Another factor in creating lucrative growth opportunities for breast cancer therapies is the increasing number of obese women. With a change in lifestyle and unhealthy food habits, the rate of obesity is increasing by the day. Obesity further causes various health problems such as cardiovascular disorders, gall bladder diseases, diabetes, breathing problems, and breast cancer, among others.
More Trending Topics from Fortune Business Insights:
